BioSpace News Archive

BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) today announced details of three presentations given from studies of NE3107 in the treatment of Parkinson’s Disease (PD) at the 2023 International Congress of Parkinson’s Disease and Movement Disorders (MDS), being held in Copenhagen, Denmark August 27-31, 2023.

Elicio Therapeutics, Inc. (Nasdaq: ELTX), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics.

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that its Chinese original equipment manufacturing (OEM) partner, A-smart MedTech (A-smart), an assisted reproductive technology company, has obtained reagent class I registrations from China’s National Medical Products Administration (NMPA) for Bionano’s DNA extraction kit and labeling products.

IceCure Medical Ltd. developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced the appointment of Mr. Shad Good, a seasoned healthcare executive, as Vice President of Sales for North America.

Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”) today announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,707,441, titled “C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using,” pertaining to the Company’s lead candidate EB-373, a psilocin prodrug being developed for the treatment of anxiety disorder.

Edwards Lifesciences Corporation (NYSE: EW) today announced it is scheduled to present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced that members of its senior management will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 at 9:30am Eastern Time.

Tourmaline Bio, Inc. announced U.S. Food and Drug Administration clearance of Tourmaline’s IND application for TOUR006.

Harbour BioMed announced that the U.S. Food and Drug Administration has cleared the investigational new drug application to commence clinical trials of its first antibody drug conjugate program HBM9033.

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, announced it has entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize ELAHERE in Japan.